248 related articles for article (PubMed ID: 18838214)
1. Prostate stem cell antigen: a prospective therapeutic and diagnostic target.
Raff AB; Gray A; Kast WM
Cancer Lett; 2009 May; 277(2):126-32. PubMed ID: 18838214
[TBL] [Abstract][Full Text] [Related]
2. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.
Reiter RE; Gu Z; Watabe T; Thomas G; Szigeti K; Davis E; Wahl M; Nisitani S; Yamashiro J; Le Beau MM; Loda M; Witte ON
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1735-40. PubMed ID: 9465086
[TBL] [Abstract][Full Text] [Related]
3. Role of prostate stem cell antigen in prostate cancer research.
Jalkut MW; Reiter RE
Curr Opin Urol; 2002 Sep; 12(5):401-6. PubMed ID: 12172427
[TBL] [Abstract][Full Text] [Related]
4. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer.
Gu Z; Thomas G; Yamashiro J; Shintaku IP; Dorey F; Raitano A; Witte ON; Said JW; Loda M; Reiter RE
Oncogene; 2000 Mar; 19(10):1288-96. PubMed ID: 10713670
[TBL] [Abstract][Full Text] [Related]
5. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer.
Wente MN; Jain A; Kono E; Berberat PO; Giese T; Reber HA; Friess H; Büchler MW; Reiter RE; Hines OJ
Pancreas; 2005 Aug; 31(2):119-25. PubMed ID: 16024997
[TBL] [Abstract][Full Text] [Related]
6. Prostate stem cell antigen: a Jekyll and Hyde molecule?
Saeki N; Gu J; Yoshida T; Wu X
Clin Cancer Res; 2010 Jul; 16(14):3533-8. PubMed ID: 20501618
[TBL] [Abstract][Full Text] [Related]
7. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
8. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
9. Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications.
Yang X; Guo Z; Liu Y; Si T; Yu H; Li B; Tian W
Expert Rev Anticancer Ther; 2014 Jan; 14(1):31-7. PubMed ID: 24308679
[TBL] [Abstract][Full Text] [Related]
10. MRl of prostate cancer antigen expression for diagnosis and immunotherapy.
Ren J; Wang F; Wei G; Yang Y; Liu Y; Wei M; Huan Y; Larson AC; Zhang Z
PLoS One; 2012; 7(6):e38350. PubMed ID: 22761679
[TBL] [Abstract][Full Text] [Related]
11. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
12. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
13. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
14. Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression.
Dubey P; Wu H; Reiter RE; Witte ON
Cancer Res; 2001 Apr; 61(8):3256-61. PubMed ID: 11309275
[TBL] [Abstract][Full Text] [Related]
15. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.
Saffran DC; Raitano AB; Hubert RS; Witte ON; Reiter RE; Jakobovits A
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2658-63. PubMed ID: 11226295
[TBL] [Abstract][Full Text] [Related]
16. Small interference RNA-mediated silencing of prostate stem cell antigen attenuates growth, reduces migration and invasion of human prostate cancer PC-3M cells.
Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
Urol Oncol; 2013 Apr; 31(3):343-51. PubMed ID: 21429770
[TBL] [Abstract][Full Text] [Related]
17. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A
Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652
[TBL] [Abstract][Full Text] [Related]
18. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.
Arndt C; Feldmann A; Töpfer K; Koristka S; Cartellieri M; Temme A; Ehninger A; Ehninger G; Bachmann M
Prostate; 2014 Sep; 74(13):1347-58. PubMed ID: 25053504
[TBL] [Abstract][Full Text] [Related]
19. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
Zhao Z; He J; Kang R; Zhao S; Liu L; Li F
Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693
[TBL] [Abstract][Full Text] [Related]
20. The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer.
Xiang Q; Zhu Z; Luo L; Wang J; Liu Y; Deng Y; Zhou M; Zhao Z
Biomed Res Int; 2020; 2020():5395312. PubMed ID: 33029516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
